Outlook Therapeutics Inc OTLK:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$1.02NASDAQ Closing Price as of 4:00PM ET 7/01/22

Today's Change0.00(0.00%)
Bid (Size)$1.00 (20)
Ask (Size)$1.05 (50)
Day Low / High$1.00 - 1.05
Volume376.8 K
Sell
Buy

Outlook Therapeutics Submits Biologics License Application for Wet Age-Related Macular Degeneration Treatment

10:14AM ET 3/31/2022 MT Newswires
Outlook Therapeutics (OTLK) said Thursday it submitted a biologics license application to the Food and Drug Administration for its ONS-5010 investigational therapy to treat wet age-related macular degeneration.

The biopharmaceutical company said it expects to receive marketing approval in late 2022 or early 2023.

If approved, the therapy will be branded as Lytenava and is likely to receive marketing exclusivity for 12 years, the company said.

Shares were 1.3% lower in morning trading on Thursday.

Most Popular Keyword Searches

MJNA JCP BABA F MSFT amd znga AAPL spy bac TWTR GE FNMA GPRO amzn ddd NFLX Enter Symbol or Name tsla FB